NCT07690826尚未招募2 期
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 252
- 试验地点
- 1
- 主要终点
- Percent Change From Baseline in Body Weight
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent.
- •Male or female adults aged 18 to 65 years.
- •BMI: 28.0 to 40.0 kg/m
- •Self-reported diet and exercise control for at least 3 months before screening, with body weight change of no more than 5 kg during the previous 3 months.
排除标准
- •Endocrine disease or history that may have a significant effect on body weight;
- •History of diabetes mellitus (gestational diabetes excepted);
- •Malignancy of any organ system within the past 5 years, irrespective of evidence of local recurrence or metastasis, except for adequately treated localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and prostate carcinoma in situ;
- •Presence or suspicion of depression, anxiety disorder, bipolar disorder, suicidal ideation, schizophrenia, or other clinically significant psychiatric disorder, or a history of suicide attempt;
- •Known or suspected excessive alcohol use, or a history of alcohol, drug, or substance abuse;
- •Acute or chronic hepatitis, or a history of severe hepatic disease other than metabolic dysfunction-associated fatty liver disease;
- •Prior or planned organ or bone marrow transplantation during the study period;
- •Any hematologic disorder that may interfere with the determination of HbA1c;
- •An autoimmune disease for which systemic corticosteroid or immunosuppressive therapy is planned during the study period;
- •Use of any medication or treatment likely to cause clinically significant weight gain or weight loss within 3 months prior to screening;
- •Participation in any clinical trial of an investigational drug or medical device within 3 months prior to screening;
- •Blood donation or blood loss ≥400 mL, or receipt of a blood transfusion, within 3 months prior to screening;
- •Mental incapacity or language impairment sufficient to preclude adequate understanding of, or participation in, the trial procedures;
- •Investigators, site staff, or other personnel directly involved in conduct of the study, and their immediate family members; employees of the Sponsor;
- •Any condition that, in the investigator's judgment, would compromise participant safety or otherwise interfere with the assessment of study results.
结局指标
主要结局
Percent Change From Baseline in Body Weight
时间窗: Baseline, Week 32
次要结局
- Change from Baseline in Glucose Level(Baseline, Week 32 and 40)
- TEAEs(Baseline, Week 44)
- Percent Change From Baseline in Body Weight(Baseline, Week 40)
- Change From Baseline in Body Weight(Baseline, Week 32 and 40)
- Change from Baseline in Body Mass Index (BMI)(Baseline, Week 32 and 40)
- Change from Baseline in Waist Circumference(Baseline, Week 32 and 40)
- Change from Baseline in Blood Pressure(Baseline, Week 32 and 40)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489Nanjing Immunophage Biotech Co., Ltd144
招募中
2 期
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) NephropathyNCT07606352Sitala Bio LTD15
招募中
2 期
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s DiseaseCTRI/2024/08/072601PSI CRO Pharma India Pvt Ltd210
招募中
2 期
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT07418736CSPC ZhongQi Pharmaceutical Technology Co., Ltd.318
招募中
2 期
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisAtopic DermatitisDermatitisEczemaNCT07599813Apollo Therapeutics Ltd280